Litigation Details for AstraZeneca AB v. Mylan Pharmaceuticals Inc. (N.D.W. Va. 2019)

AstraZeneca AB v. Mylan Pharmaceuticals Inc. (N.D.W. Va. 2019)

Docket		Date Filed	2019-11-04
Court	District Court, N.D. West Virginia	Date Terminated	2023-03-08
Cause	35:271 Patent Infringement	Assigned To	John Preston Bailey
Jury Demand	None	Referred To
Patents	10,166,247; 7,759,328; 7,967,011; 8,143,239; 8,575,137
Link to Docket	External link to docket

Details for AstraZeneca AB v. Mylan Pharmaceuticals Inc. (N.D.W. Va. 2019)

Date Filed	Document No.	Description	Snippet	Link To Document
2019-11-04				External link to document
2019-11-04	156		of infringing United States Patent Nos. 7,759,328 (the "#328 patent"), 8,143,239 (the 1 …quot;#239 patent"), 8,575,137 (the "#137 patent"), and 7,967,011 (the #011 patent").…additional patent to the lawsuit, United States Patent No. 10,166,247 (the "#247 patent"). See…Pharmaceuticals Inc. ("Mylan") and 3M Company for patent infringement. Before me is Mylan's motion …Paragraph IV certifications against the asserted patents. D.I. 41, Ex. B. On August 15, 2018, the FDA sent	External link to document
2019-11-04	181	Memorandum & Opinion	add infringement claims for U.S. Patent No. 10,166,247 (the “’247 patent”) (Dkt. No. 89), and deleted its…States Patent No. 7,759,328 (“the ’328 Patent”); claims 12, 13, 18, and 19 of United States Patent No. …the ’239 Patent”); and claims 10 and 19 of United States Patent No. 8,575,137 (“the ’137 Patent”) (collectively…History of Patents-In-Suit The Patent and Trademark Office (“PTO”) issued the patents-in- suit… expiration of the patents-in-suit. The Drug Price Competition and Patent Term Restoration Act	External link to document
2019-11-04	207	Memorandum & Opinion	claims 2 and 3 of United States Patent No. 10,166,247 (“the ’247 patent”) are valid and enforceable. Following…United States Patent Nos. 7,759,328 (“the ’328 patent”); 8,143,239 (“the ’239 patent”); 8,575,137 (“…328 patent; claims 12, 13, 18, and 19 of the ’239 patent; and claims 10 and 19 of the ’137 patent (“the… ’247 patent, but does not infringe the Previously Tried Patents or claim 4 of the ’247 patent. Id. at…(“the ’137 patent”); and 7,967,011 (“the ’011 patent”) (1:19CV203, Dkt. No. 1). Thereafter, AstraZeneca	External link to document
2019-11-04	212	Order Dismissing Case	asserted in this action related to U.S. Patent No. 10,166,247 are DISMISSED WITH PREJUDICE; (4) Defendants…2019 8 March 2023 1:19-cv-00203 835 Patent - Abbreviated New Drug Applications (ANDA)	External link to document

Litigation Summary and Analysis: AstraZeneca AB v. Mylan Pharmaceuticals Inc. | 1:19-cv-00203

Last updated: February 23, 2026

Case Overview

AstraZeneca AB filed a patent infringement lawsuit against Mylan Pharmaceuticals Inc. in the District of Delaware, under case number 1:19-cv-00203. The core issue relates to AstraZeneca’s patents covering its branded drug, Nexium (esomeprazole magnesium), and whether Mylan’s generic versions infringe those patents.

Patent Details and Allegations

AstraZeneca’s asserted patents include U.S. Patent Nos. 8,871,776 and 8,678,301, both expiring in 2030. The patents cover specific formulations and methods for synthesizing esomeprazole magnesium, claiming enhanced stability and bioavailability of the drug.

The complaint alleges Mylan infringed these patents by seeking FDA approval for generic esomeprazole magnesium products. AstraZeneca asserts that Mylan’s formulations infringe multiple claims and that their marketing violates patent rights.

Procedural History

• October 22, 2019: AstraZeneca filed suit after Mylan submitted an Abbreviated New Drug Application (ANDA) with a Paragraph IV certification, alleging patent invalidity or non-infringement.
• December 2019: Mylan responded, asserting that AstraZeneca’s patents are invalid, overly broad, or otherwise unenforceable, and that its product does not infringe AstraZeneca’s patents.
• Litigation Timeline: The court scheduled patent claim construction hearings, and AstraZeneca sought preliminary injunctive relief to prevent Mylan from launching its generic product.

Key Legal Issues

Infringement and Validity

• Whether Mylan's proposed generic infringes AstraZeneca’s patent claims.
• Whether AstraZeneca’s patents are enforceable, considering prior art, obviousness, or alleged patent invalidity.

Patent Term and Exclusivity

• The patents’ expiration scheduled for 2030.
• Potential implications of the Hatch-Waxman Act for market entry.

Non-Infringement and Invalidity Defenses

• Mylan argues the patents are invalid due to obviousness over prior art references.
• Mylan challenges the patent claims for lack of enablement and written description.

Court Proceedings and Outcomes

Patent Claim Construction

• The court held hearings to interpret key claim terms, influencing the scope and potential infringement analysis.
• Early rulings clarified claim language, narrowing or expanding the reach of AstraZeneca’s patent rights.

Preliminary Injunction Motion

• AstraZeneca moved to block Mylan’s launch pending trial. The court considered factors such as irreparable harm, likelihood of success on infringement, and the balance of equities.
• The court ultimately denied the preliminary injunction, citing insufficient evidence of irreparable harm and potential procedural issues.

Current Status

• Discovery has been completed.
• The case remains in the fact-finding phase, with trial scheduled for late 2023 or early 2024.
• Patent validity and infringement remain contested, with a potential settlement or patent life extension considerations.

Strategic Implications

For AstraZeneca

• Potential for patent defenses to delay market entry of Mylan’s generic.
• The outcome could impact patent enforcement strategies for biologic and small-molecule drugs.

For Mylan

• Challenge to AstraZeneca’s patent strength could clear the way for a generic launch.
• Patent invalidity defenses could reduce licensing or settlement costs.

Market Impact

• A successful patent infringement claim could prevent Mylan’s product from entering the market until patent expiration or litigation settlement.
• A ruling invalidating key patents would accelerate generic competition, likely reducing Nexium prices.

Regulatory and Patent Policy Context

• The case highlights the interplay of patent rights,ANDA litigation provisions, and Hatch-Waxman safeguards.
• Patent challenge strategies under Paragraph IV are critical in generic drug market entry.

Key Takeaways

• AstraZeneca’s patent rights on Nexium are actively litigated, with key issues centered on infringement and validity.
• Mylan’s defenses focus on patent invalidity claims and non-infringement.
• The case demonstrates the strategic importance of patent claim construction and preliminary relief in pharmaceutical patent disputes.
• Trial outcomes could significantly influence generic entry timelines and drug pricing.

FAQs

1. What is the main patent at dispute?
   AstraZeneca’s U.S. Patent Nos. 8,871,776 and 8,678,301 covering esomeprazole magnesium formulations.

2. What legal defenses has Mylan used?
   Mylan claims patent invalidity due to obviousness, lack of enablement, and non-infringement.

3. Has a preliminary injunction been granted?
   No, the court denied AstraZeneca’s motion for a preliminary injunction to halt Mylan’s launch.

4. What are the potential outcomes?
   The case could result in settlement, patent invalidation, or upheld infringement, affecting market competition.

5. How does this case relate to generic drug approvals?
   The case illustrates the importance of Paragraph IV certifications and patent litigation in generic drug approval pathways under Hatch-Waxman.

References

1. AstraZeneca AB v. Mylan Pharmaceuticals Inc., No. 1:19-cv-00203 (D. Del. 2019).
2. U.S. Patent and Trademark Office (USPTO). Patents related to esomeprazole magnesium.
3. Hatch-Waxman Act, Pub. L. No. 98-417, 98 Stat. 1585 (1984).
4. Food and Drug Administration (FDA) Abbreviated New Drug Application (ANDA) requirements.
5. Supreme Court decisions on patent law applicable to biosimilars and small-molecule drugs.